Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QHRD110 plus temozolomide in recurrent/progressive high-grade glioma
CTR20260040Phase 2Active
- Sponsor
- Qianhong Biopharmaceutical
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of QHRD110 in glioma, sponsored by Qianhong Biopharmaceutical. Started Mar 2026; status: active.
02
Drugs
QHRD110
03
Conditions
glioma
Beyond the preview
Go deeper on CTR20260040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260040.